Dietmar Berger, Sanofi CMO
Sanofi nabs priority review for hemophilia A program as pharma awaits FDA decision
Sanofi has been setting itself up for a rematch against other pharmas in the hemophilia space, and thanks to the FDA, the company is now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
